Carr Financial Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
Carr Financial Group's AKBA Position: Q3 2026 in Review
Carr Financial Group sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 15,581 shares — an estimated $17.8K sold.
Carr Financial Group first reported a position in AKBA in Q4 2025 and held it in 3 quarters. The position peaked at $21.7K in Q1 2026. 128 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- Carr Financial Group reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
- Carr Financial Group sold 15,581 Akebia Therapeutics shares in Q3 2026, an estimated $17.8K.
- Carr Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and held it in 3 quarters.
- Carr Financial Group's Akebia Therapeutics position peaked at $21.7K in Q1 2026.
- 128 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on Carr Financial Group's 13F filing for Q3 2026, filed 10 Nov 2026.